InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,196.93
(
0.31%
)
US TECH 100
17,666.40
(
0.32%
)
Dow Jones
38,920.23
(
0.17%
)
Brent Oil
83.47
(
-0.01%
)
Bitcoin
63,473.65
(
0.49%
)
Post# of 129051
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DouglasJH

Send PM Follow Ignore
Followers 0
Posts 857
Boards Moderated 0
Alias Born 08/28/2009

DouglasJH

Re: None

Thursday, 12/30/2010 6:16:36 PM

Thursday, December 30, 2010 6:16:36 PM

Post# of 129051
FDA plays can be rewarding. Especially when they make submissions or advancements in the FDA process. IMO, the company could have plans on using that news to bouy the new class of shares as well as using the Berkshire structure of 30:1 to entice investors.

One company last Thursday bounced on news that it had submitted additional data to the FDA from three different studies for its experimental testosterone deficiency drug.

Shares of Repros (NasdaqCM:RPRX) nearly doubled on the news, rocketing 82% or $1.15 to $2.56

Read the full report: http://biomedreports.com/2010122461781/rxnews-recap-for-12-23-10.html#ixzz19dgTcqOQ
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up